EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Cost‐effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare settings

Richard Tuson iD, Andrew Metry iD, Keith Harding iD

International Wound Journal · 2024

DOI: 10.1111/iwj.70048 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Wound Journal, 2024. Verfasst von Richard Tuson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Analytical Solutions Ltd, Macclesfield, UK. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Varicose Ulcer, Wound Healing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the cost‐effectiveness of the geko device a neuromuscular electro‐stimulator technology with standard of care (SoC) versus SoC alone for venous leg ulcer (VLU) treatment, from the UK National Health Service (NHS) perspective over 12 months. Research was conducted across NHS UK facilities, primarily within community services and outpatient leg ulcer clinics, encompassing a total of 51 patients. A partitioned survival model, based on a two‐arm randomised controlled trial, assessed wound healing rates using Kaplan–Meier curves and parametric extrapolations over a 12‐month time horizon. Costs were derived from UK reference costs the British National Formulary, and the Personal Social Services Research Unit (2021/22). The primary outcome measured was the incremental cost per quality‐adjusted life‐year gained. The geko device provides additional benefits by stimulating the lateral popliteal nerve, augmenting venous, arterial, and microvascular flow. The addition of the geko device to SoC significantly enhanced outcomes, increasing healing probability by 68% compared to SoC. This integration would result in a cost saving of £774.14 per patient when compared to the SoC alone across the NHS. Economic analyses indicate that integrating the geko device into SoC protocols would reduce the overall NHS expenditure on VLU wound management by as much as 15%. The approach also positively impacted health‐related quality of life. The geko™ device when used adjunctively with SoC would be a cost‐effective method for managing chronic VLUs within the NHS, improving healing rates and offering economic benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisVaricose UlcerWound HealingHumansUnited KingdomMaleFemaleAgedMiddle AgedState MedicineElectric Stimulation TherapyQuality-Adjusted Life YearsAged, 80 and overCost-Effectiveness Analysis

Stichwörter der Autor:innen

NMEScost savingcost‐effectivenessvenous leg ulcerswound management

Autor:innen und Institutionen

  • Health Analytical Solutions Ltd, Macclesfield, UK.

ORCID-Profile: Richard Tuson, Andrew Metry, Keith Harding

Zitieren

APA

Tuson, R., Metry, A., & Harding, K. (2024). Cost‐effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare settings. International Wound Journal. https://doi.org/10.1111/iwj.70048

Vancouver

Tuson R, Metry A, Harding K. Cost‐effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare settings. International Wound Journal. 2024. doi:10.1111/iwj.70048

BibTeX
@article{Tuson2024,
  author = {Tuson, Richard and Metry, Andrew and Harding, Keith},
  title = {Cost‐effectiveness analysis of the geko™ device (an NMES technology) in managing venous leg ulcers in UK healthcare settings},
  journal = {International Wound Journal},
  year = {2024},
  doi = {10.1111/iwj.70048}
}
Kostenlos starten →